JP2017534253A5 - - Google Patents

Info

Publication number

JP2017534253A5

JP2017534253A5 JP2017513637A JP2017513637A JP2017534253A5 JP 2017534253 A5 JP2017534253 A5 JP 2017534253A5 JP 2017513637 A JP2017513637 A JP 2017513637A JP 2017513637 A JP2017513637 A JP 2017513637A JP 2017534253 A5 JP2017534253 A5 JP 2017534253A5

Authority

JP

Japan

Prior art keywords

her2

antibody

immune complex

seq

binds

Prior art date

2015-09-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims description 46
• 229940079593 drug Drugs 0.000 claims description 4
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 3
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 44
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 40
• 201000011510 cancer Diseases 0.000 claims 19
• 206010028980 Neoplasm Diseases 0.000 claims 18
• 125000003275 alpha amino acid group Chemical group 0.000 claims 18
• 229940124597 therapeutic agent Drugs 0.000 claims 15
• 229940127089 cytotoxic agent Drugs 0.000 claims 12
• 239000002254 cytotoxic agent Substances 0.000 claims 11
• 239000000825 pharmaceutical preparation Substances 0.000 claims 10
• 238000000034 method Methods 0.000 claims 8
• 206010006187 Breast cancer Diseases 0.000 claims 7
• 208000026310 Breast neoplasm Diseases 0.000 claims 7
• 231100000599 cytotoxic agent Toxicity 0.000 claims 7
• 229960002087 pertuzumab Drugs 0.000 claims 7
• 125000005647 linker group Chemical group 0.000 claims 6
• 208000005718 Stomach Neoplasms Diseases 0.000 claims 5
• 125000003118 aryl group Chemical group 0.000 claims 5
• 206010017758 gastric cancer Diseases 0.000 claims 5
• 201000011549 stomach cancer Diseases 0.000 claims 5
• 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 4
• 125000002947 alkylene group Chemical group 0.000 claims 4
• 239000012472 biological sample Substances 0.000 claims 4
• 125000005843 halogen group Chemical group 0.000 claims 4
• 102000051957 human ERBB2 Human genes 0.000 claims 4
• 229910052739 hydrogen Inorganic materials 0.000 claims 4
• 229960000575 trastuzumab Drugs 0.000 claims 4
• 206010038111 Recurrent cancer Diseases 0.000 claims 3
• 238000001514 detection method Methods 0.000 claims 3
• 238000010494 dissociation reaction Methods 0.000 claims 3
• 230000005593 dissociations Effects 0.000 claims 3
• 125000001072 heteroaryl group Chemical group 0.000 claims 3
• 229910052760 oxygen Inorganic materials 0.000 claims 3
• 229910052717 sulfur Inorganic materials 0.000 claims 3
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 3
• RHKRZQHJRZVTBP-UHFFFAOYSA-N 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole Chemical compound C1=CC=CC2=C3C(CCl)CNC3=CC=C21 RHKRZQHJRZVTBP-UHFFFAOYSA-N 0.000 claims 2
• 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
• 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
• 206010055113 Breast cancer metastatic Diseases 0.000 claims 2
• 125000004450 alkenylene group Chemical group 0.000 claims 2
• 125000000217 alkyl group Chemical group 0.000 claims 2
• 239000003937 drug carrier Substances 0.000 claims 2
• 229940127121 immunoconjugate Drugs 0.000 claims 2
• 230000002401 inhibitory effect Effects 0.000 claims 2
• 230000035772 mutation Effects 0.000 claims 2
• 229910052757 nitrogen Inorganic materials 0.000 claims 2
• 102000039446 nucleic acids Human genes 0.000 claims 2
• 150000007523 nucleic acids Chemical class 0.000 claims 2
• 108020004707 nucleic acids Proteins 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 229910052698 phosphorus Inorganic materials 0.000 claims 2
• 125000001963 4 membered heterocyclic group Chemical group 0.000 claims 1
• UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims 1
• 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
• 108091005804 Peptidases Proteins 0.000 claims 1
• 239000004365 Protease Substances 0.000 claims 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
• 239000002253 acid Substances 0.000 claims 1
• 238000009098 adjuvant therapy Methods 0.000 claims 1
• 150000001413 amino acids Chemical class 0.000 claims 1
• 239000002246 antineoplastic agent Substances 0.000 claims 1
• 108010044540 auristatin Proteins 0.000 claims 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
• 210000000481 breast Anatomy 0.000 claims 1
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
• 229930195731 calicheamicin Natural products 0.000 claims 1
• 150000001768 cations Chemical class 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 125000005842 heteroatom Chemical group 0.000 claims 1
• 125000000623 heterocyclic group Chemical group 0.000 claims 1
• 150000007857 hydrazones Chemical class 0.000 claims 1
• 238000000338 in vitro Methods 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000002184 metal Substances 0.000 claims 1
• 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
• YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 1
• 238000011470 radical surgery Methods 0.000 claims 1
• 239000000523 sample Substances 0.000 claims 1
• 229960001612 trastuzumab emtansine Drugs 0.000 claims 1
• 229910019142 PO4 Inorganic materials 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• QHSXWDVVFHXHHB-UHFFFAOYSA-N 3-nitro-2-[(3-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1SSC1=NC=CC=C1[N+]([O-])=O QHSXWDVVFHXHHB-UHFFFAOYSA-N 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• CWPIBZMCMRNFHK-UHFFFAOYSA-N piperazin-1-ium;carbamate Chemical compound NC(O)=O.C1CNCCN1 CWPIBZMCMRNFHK-UHFFFAOYSA-N 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1